

Q-linea announces shipment of two ASTar® instruments to Saudi Arabia

Today Q-linea AB (publ) (OMX: QLINEA) announces two ASTar units will be shipped to hospitals in Saudi Arabia. Local partner AMICO will manage installation of the instruments for evaluations expected to convert to clinical use during 2026.

These instruments complement two ASTar units already deployed for evaluations that have been successfully completed in Kuwait and UAE. Demand for ASTar has increased across the region following successful commercialisation efforts by AMICO. It is anticipated that the first ASTar will move into routine clinical use in the region during Q2 2026 with several more expected to go live later in the year.

“The instruments will be installed in two leading health systems in Riyadh and Jeddah with the expectation they will help guide adoption decisions for the Ministry of Health”, says Sherif Harydi, Regional Commercial Director for AMICO.

“We are excited to introduce ASTar to Saudi Arabia where we see significant interest in the technology to meet patient needs”, adds Franco Pellegrini, VP EMEA Sales for Q-linea.

About AMICO

AMICO is a leading regional healthcare commercial corporation and in#vitro diagnostics (IVD) distributor with a strong presence across the Middle East, operating in 13 countries and serving the region for more than forty years. With a clear mission to bridge the gap between cutting#edge diagnostic technologies and the diverse needs of healthcare systems in the Middle East, AMICO plays a central role in accelerating access to advanced solutions across the GCC and wider region.

AMICO’s partnership with Q#linea reflects its commitment to delivering impactful, clinically relevant IVD technologies—particularly in the critical area of sepsis management—supporting hospitals and laboratories in improving antimicrobial stewardship and advancing patient outcomes.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.

Q-linea's flagship technology, ASTar[®], is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea is listed on Nasdaq Stockholm.

Attachments

[Q-linea announces shipment of two ASTar[®] instruments to Saudi Arabia](#)